Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Nov 20;28(26):3189-209.
doi: 10.1002/sim.3603.

Measurement in Clinical Trials: A Neglected Issue for Statisticians?


Measurement in Clinical Trials: A Neglected Issue for Statisticians?

Stephen Senn et al. Stat Med. .


Biostatisticians have frequently uncritically accepted the measurements provided by their medical colleagues engaged in clinical research. Such measures often involve considerable loss of information. Particularly, unfortunate is the widespread use of the so-called 'responder analysis', which may involve not only a loss of information through dichotomization, but also extravagant and unjustified causal inference regarding individual treatment effects at the patient level, and, increasingly, the use of the so-called number needed to treat scale of measurement. Other problems involve inefficient use of baseline measurements, the use of covariates measured after the start of treatment, the interpretation of titrations and composite response measures. Many of these bad practices are becoming enshrined in the regulatory guidance to the pharmaceutical industry. We consider the losses involved in inappropriate measures and suggest that statisticians should pay more attention to this aspect of their work.

Comment in

Similar articles

See all similar articles

Cited by 29 articles

See all "Cited by" articles

Publication types

MeSH terms

LinkOut - more resources